DGAP-News: MagForce AG / Key word(s): Miscellaneous
MagForce AG: MagForce USA Installs the First Clinical NanoActivator(R)
in the USA
23.11.2015 / 08:30
---------------------------------------------------------------------
MagForce USA Installs the First Clinical NanoActivator(R) in the USA
Berlin, Germany, and Nevada, USA, November 23, 2015 - MagForce AG
(Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading
medical device company in the field of nanomedicine focused on oncology,
announced today that MagForce USA, Inc., MagForce AG's US subsidiary, has
successfully installed the first clinical NanoActivator(R) in the USA. This
NanoActivator(R) is similar in design to the five NanoActivator(R) devices
operating at University Hospitals in Germany applying NanoTherm(TM) Therapy
for the treatment of Brain Tumors. However, the USA NanoActivator(R) has
been modified to apply NanoTherm(TM) Therapy for the treatment of Prostate
Cancer in addition to the treatment of Brain Tumors.
The USA NanoActivator(R) is located in Seattle, Washington, near the
University of Washington Medical Center, and will be utilized in the Focal
Thermal Ablation Registriation Study for Prostate Cancer for which the
Company has filed an Investigational Device Exemption (IDE) with The US
Food and Drug Administration (FDA) in May 2015.
About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange
(MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc.
is a leading medical device company in the field of nanomedicine focused on
oncology. The Group's proprietary NanoTherm therapy enables the targeted
treatment of solid tumors through the intratumoral generation of heat via
activation of superparamagnetic nanoparticles. Mithril Capital Management,
a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along
with MagForce AG, are investors and strategic partners in MagForce USA,
Inc.
NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the
therapy and have received EU-wide regulatory approval as medical devices
for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and
NanoActivator are trademarks of MagForce AG in selected countries.
For more information, please visit: www.magforce.com.
Disclaimer
This release may contain forward-looking statements and information which
may be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or
"will". Such forward-looking statements are based on our current
expectations and certain assumptions, which may be subject to a variety of
risks and uncertainties. The results actually achieved by MagForce AG may
substantially differ from these forward-looking statements. MagForce AG
assumes no obligation to update these forward-looking statements or to
correct them in case of developments, which differ from those, anticipated.
Contact:
Anne Hennecke
MC Services AG
T +49 211 529252-22
F +49 211 529252-29
Email: anne.hennecke@mc-services.eu
---------------------------------------------------------------------
23.11.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MagForce AG
Max-Planck-StraÃe 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail: info@magforce.com
Internet: www.magforce.com
ISIN: DE000A0HGQF5
WKN: A0HGQF
Listed: Regulated Unofficial Market in Berlin, Dusseldorf,
Stuttgart; Open Market (Entry Standard) in Frankfurt
End of News DGAP News Service
---------------------------------------------------------------------
415307 23.11.2015
DGAP-News: MagForce AG: MagForce USA Installs the First Clinical NanoActivator(R) in the USA
| Source: EQS Group AG